Vertex Pharmaceuticals and Ono Pharmaceutical Co., Ltd. announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of BAFF and APRIL, being studied for IgA Nephropathy (IgAN), primary membranous nephropathy (pMN), and other B cell-mediated diseases.
Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory and commercial milestone payments and tiered royalties. Ono will leverage its expertise in clinical development and commercialization for chronic kidney disease in Japan and South Korea to accelerate the advancement of povetacicept.
Ono will be responsible for obtaining marketing authorizations and solely commercializing povetacicept in these regions following approval. This strategic partnership aims to deliver povetacicept to thousands of potential patients in Japan and South Korea, expanding its global reach.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.